Gilead Sciences (GILD) FCF Margin (2009 - 2026)
Gilead Sciences' (GILD) quarterly FCF Margin came in at 34.87% in Q1 2026, up 1008.0% YoY from 3.15% in Q1 2025, and down 11.48% on a QoQ basis from 39.39% in Q4 2025.
Gilead Sciences (GILD) FCF Margin (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of FCF Margin data on file, last reported at 34.87% in Q1 2026.
- Quarterly FCF Margin rose 1008.0% year-over-year to 34.87% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 34.4% (up 14.0% YoY) and the FY2025 annual result came in at 32.12%, down 372.0% from the prior year.
- FCF Margin slipped to 34.87% in Q1 2026, from 39.39% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 55.24% in Q3 2024 to a low of 10.17% in Q2 2025.
- A 5-year average of 31.34% and a median of 31.62% in 2024 frame the typical range for FCF Margin.
- The widest YoY moves for FCF Margin: up 3208 bps in 2024, down 1614 bps in 2024.
- Tracing GILD's FCF Margin over 5 years: stood at 32.29% in 2022, then dropped by 15 bps to 27.47% in 2023, then surged by 36 bps to 37.36% in 2024, then advanced by 5 bps to 39.39% in 2025, then decreased by 11 bps to 34.87% in 2026.
- The last three FCF Margin figures came in at 34.87% (Q1 2026), 39.39% (Q4 2025), and 50.98% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 28.82% |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 18.33% |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 26.96% |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 38.60% |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | -12.07% |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 34.70% |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 44.00% |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 2.01% |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 3.90% |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 18.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44.00% |
| Mar 31, 2026 | 34.87% |
| Dec 31, 2025 | 39.39% |
| Sep 30, 2025 | 50.98% |
| Jun 30, 2025 | 10.17% |
| Mar 31, 2025 | 24.79% |
| Dec 31, 2024 | 37.36% |
| Sep 30, 2024 | 55.24% |
| Jun 30, 2024 | 17.18% |
| Mar 31, 2024 | 31.62% |
| Dec 31, 2023 | 27.47% |
| Sep 30, 2023 | 23.16% |
| Jun 30, 2023 | 33.32% |
| Mar 31, 2023 | 25.74% |
| Dec 31, 2022 | 32.29% |
| Sep 30, 2022 | 38.43% |
| Jun 30, 2022 | 26.50% |
| Mar 31, 2022 | 24.17% |
| Dec 31, 2021 | 42.09% |
| Sep 30, 2021 | 41.96% |